Wissenschaftl. Titel | A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish) |
Erkrankung |
Gastro:
Magen-/Ösophaguskarzinom:
Alle Linien
|
Kurzprotokoll | Kurzprotokoll |
Links | Weiterführende Informationen (HD) Weiterführende Informationen (NIH) |
erstellt 28.12.2023 Data entry III CCP
geändert 25.09.2024 Data entry III CCP